Free Trial
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

$0.96
0.00 (0.00%)
(As of 07/19/2024 ET)
Today's Range
$0.96
$0.96
50-Day Range
$0.62
$1.49
52-Week Range
$0.39
$18.00
Volume
1,909 shs
Average Volume
2,341 shs
Market Capitalization
$4.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ARTH stock logo

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

ARTH Stock Price History

ARTH Stock News Headlines

Arch Therapeutics, Inc. (OTCMKTS:ARTH) Short Interest Update
49 wins… 3 losses… You do the math
The markets are chaotic right now… and yet, over the last year, my flagship strategy has issued a NEW trade every single week… All while maintaining a 49-3 win/loss record! How is that possible? It’s all thanks to a little move I call the “Tuesday Bear Trap…” See, when the markets open Tuesday, I use my proprietary trading tools AND my personal expertise, and I judge the direction of the overall market. Then, my flagship strategy finds a trade in the same direction on a trend stock… After that, it’s just a straightforward 2-step trade to target income week after week after week.
Arch Therapeutics Inc ARTH
49 wins… 3 losses… You do the math
The markets are chaotic right now… and yet, over the last year, my flagship strategy has issued a NEW trade every single week… All while maintaining a 49-3 win/loss record! How is that possible? It’s all thanks to a little move I call the “Tuesday Bear Trap…” See, when the markets open Tuesday, I use my proprietary trading tools AND my personal expertise, and I judge the direction of the overall market. Then, my flagship strategy finds a trade in the same direction on a trend stock… After that, it’s just a straightforward 2-step trade to target income week after week after week.
Arch Therapeutics Provides Year End Operational Update
Arch Therapeutics Provides AC5® Commercialization Update
Dr. Arth Patel
Double Arch
See More Headlines
Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
7/20/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-6,980,000.00
Net Margins
-6,460.51%
Pretax Margin
-6,460.51%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($2.43) per share

Miscellaneous

Free Float
4,529,000
Market Cap
$4.55 million
Optionable
Not Optionable
Beta
3.59
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Terrence W. Norchi M.D. (Age 59)
    Co-Founder, Chairman, President & CEO
    Comp: $450.5k
  • Mr. Michael S. Abrams (Age 54)
    CFO & Treasurer
    Comp: $325k
  • Dr. Rutledge Ellis-Behnke Ph.D.
    Co-Founder & Scientific Advisor
  • Mr. Shawn Carlson
    Vice President of Sales

ARTH Stock Analysis - Frequently Asked Questions

How have ARTH shares performed this year?

Arch Therapeutics' stock was trading at $7.24 on January 1st, 2024. Since then, ARTH stock has decreased by 86.7% and is now trading at $0.96.
View the best growth stocks for 2024 here
.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) posted its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.33) earnings per share for the quarter. The biotechnology company had revenue of $0.03 million for the quarter.

How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Arch Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX) and Bellerophon Therapeutics (BLPH).

This page (OTCMKTS:ARTH) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners